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Abstract
Understanding the benefits and risks of treatments to be used by older individuals
(≥65 years old) is critical for informed therapeutic decisions. Glucose-lowering therapy
for older patients with diabetes should be tailored to suit their clinical condition, com-
orbidities and impaired functional status, including varying degrees of frailty. However,
despite the rapidly growing population of older adults with diabetes, there are few
dedicated clinical trials evaluating glucose-lowering treatment in older people. Con-
ducting clinical trials in the older population poses multiple significant challenges.
Despite the general agreement that individualizing treatment goals and avoiding
hypoglycaemia is paramount for the therapy of older people with diabetes, there are
conflicting perspectives on specific glycaemic targets that should be adopted and on
use of specific drugs and treatment strategies. Assessment of functional status, frailty
and comorbidities is not routinely performed in diabetes trials, contributing to insuffi-
cient characterization of older study participants. Moreover, significant operational bar-
riers and problems make successful enrolment and completion of such studies difficult.
In this review paper, we summarize the current guidelines and literature on conducting
such trials, as well as the learnings from our own clinical trial (IMPERIUM) that assessed
different glucose-lowering strategies in older people with type 2 diabetes. We discuss
the importance of strategies to improve study design, enrolment and attrition. Apart
from summarizing some practical advice to facilitate the successful conduct of studies,
we highlight key gaps and needs that warrant further research.
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1 | INTRODUCTION
The growing diabetes pandemic coupled with significant improvements
in medical care has resulted in a rise in an older population with diabe-
tes (≥65 years old). The International Diabetes Federation estimated a
global diabetes prevalence of 9.6% in people older than 65 years.1 It is
much higher in some countries such as the United States where 25% of
adults ≥65 years of age were diagnosed with diabetes and about 48%
with prediabetes as of 2015.2 This prevalence is estimated to increase
4.5-fold from 2005 to 2050 in those ≥65 years of age.3
Older people with diabetes comprise a heterogeneous population
with unique medical, psychological and social needs. They often have
a number of geriatric syndromes such as frailty, cognitive impairment,
depression, urinary incontinence, falls and fractures, vision and hearing
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impairment, and persistent pain, which add to the complexity and bur-
den of diabetes.4 Frailty is of particular relevance because frail older
individuals have lower functional reserves and are more vulnerable to
comorbidities, adverse events and mortality. Frailty may also change the
course and natural history of diabetes and trigger the need for modifica-
tions of glucose-lowering treatment. Weight loss, which is typically
associated with frailty, may reverse the tendency to hyperglycaemia,
promote normoglycaemia and increase the risk of hypoglycaemic epi-
sodes with or without pharmacological therapy.5
Older patients with diabetes may also have several comorbidities
such as cardiovascular disease and microvascular complications.4 This
increases the use of prescription and over-the-counter medications,
resulting in higher rates of polypharmacy in older adults.6 In 2011,
>85% of people in the United States aged 62-85 years used at least
one, and more than one-third of them used five or more prescription
medicines.7 Polypharmacy increases the risk of drug interactions and
adverse events.8 Other age-related phenomena such as impairment of
renal or hepatic excretory function might result in altered pharmacoki-
netics of the drugs, making older patients more vulnerable to adverse
events, including hypoglycaemia, than younger patients.
Hypoglycaemia in older people receiving glucose-lowering ther-
apy may carry a significant risk of morbidity and mortality.9,10 The
consequences of hypoglycaemia range from life-threatening cardio-
vascular events triggered by severe hypoglycaemia episodes to physi-
cal and cognitive dysfunction, frailty, disability and mortality resulting
from repeated non-severe episodes.11
Acknowledging the differences between older and younger
patients, the International Conference on Harmonization (ICH) guide-
line on geriatrics (E7)12 called for the inclusion of representative older
patients with concomitant therapies and comorbidities in drug devel-
opment trials (Table 1). The ICH guideline has been adopted by regu-
latory bodies including the European Medicines Agency (EMA)14 and
the US Food and Drug Administration (FDA) and six other ICH mem-
ber countries.15 Table 1 provides a summary of requirements set by
the ICH and EMA regarding the inclusion of older patients in drug
development clinical trials.
Besides pharmacokinetics, pharmacodynamics, safety and effi-
cacy of the drug, other aspects of drug therapy such as patient
acceptability, dosage and route of administration, dosing frequency,
formulations, excipients, container closures, devices, technologies,
product information, medication management and recognition might
be very relevant for older drug users and have been discussed in the
reflection paper on the pharmaceutical development of medicines for
use in the older population published by the EMA.14
This review summarizes current literature and guidelines on con-
ducting clinical trials evaluating glucose-lowering therapies in older
patients with diabetes. We also share our experience with regards to
the planning, designing, implementing and reporting of clinical trials
involving older patients in need of glucose-lowering therapy based on
our learnings from the randomized clinical trial entitled, “Individualized
treatMent aPproach for oldER vulnerable patIents; a randomized,
controlled stUdy in type 2 diabetes Mellitus” (IMPERIUM study;
NCT02072096).16 This was the first study conducted in vulnerable
adults ≥65 years of age with type 2 diabetes, which aimed at evaluat-
ing different treatment strategies to lower blood glucose in frail older
patients.
2 | WHY IS IT DIFFICULT TO CONDUCT
DIABETES TRIALS IN OLDER PATIENTS?
Despite significant progress in diabetes clinical research, information
about outcomes of glucose-lowering treatments in older patients
remains limited. Understanding the reasons behind such scarcity of
data may help develop solutions for this problem.
2.1 | Conflicting perspectives on treatment goals
It is widely accepted that blood glucose should be lowered in older
patients with diabetes while reducing or even avoiding the risk of
hypoglycaemia.1,4,17 The extent to which blood glucose should be
TABLE 1 Regulatory guidance on inclusion of older patients in clinical trials
Guidance
ICH E712 • Trial population should be representative of the population that will use the drug.
 Call for inclusion of patients that are ≥75 years old and receiving treatments or having medical problems common in
geriatric populations.
• Exclusion of patients based on upper age limits, comorbid conditions and concomitant illnesses is no longer justified (unless
there is a reason to believe that inclusion may endanger them or lead to difficulties in interpreting study results).
• Phase 2 and 3 trials should include a minimum meaningful number of older participants.
 For medicines intending to treat diseases present in older patients but not unique to them, at least 100 participants
should be ≥65 years old (with the exception of uncommon diseases).
 For medicines intended for diseases associated with ageing, ≥50% of participants should be ≥65 years old.
EMA13 • Requires “reasonable” number of older patients (of age 65-74, 75-84 and 85+ years old) that will allow presentation of data
for these age groups to confirm their consistency with results obtained from younger populations.
• Calls for functional characterization of older patients participating in the trials to ensure that they truly represent the target
patient population and include vulnerable (frail) geriatric patients.
• Recommends use of the short physical performance battery or gait speed as the instruments that best fulfil criteria of the
prognostic value, validation status, feasibility and ease of use, time needed, ease of investigator's training, and cost.
Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; ICH, International Conference on Harmonisation.
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lowered, the best ways to achieve glycaemic targets and the choice of
glucose-lowering therapies are frequently extrapolated from studies
conducted in younger individuals.
A belief that older patients may benefit from normalizing blood
glucose levels may lead to setting overly ambitious glycaemic goals for
participants of clinical trials and ultimately to their “overtreatment” in
real-world clinical practice.18-20 While there is an agreement that gly-
cated haemoglobin (HbA1c) of ≤7% (≤53 mmol/mol) is a reasonable
target for most adults, the assumption that lowering blood glucose
reduces microvascular complications, as well as prevents cardiovascu-
lar events may not be true for patients with a short life expectancy.21
The risk of adverse events with glucose-lowering treatment may out-
weigh the benefits of preventing microvascular complications in frail
older patients. A range of alternative glycaemic targets have been pro-
posed for older patients with diabetes, e.g., <7.5% (<59 mmol/mol),
<8.0% (<64 mmol/mol), <8.5% (<69 mmol/mol) or 8.0%-9.0%
(64-75 mmol/mol), depending on the overall health status, duration of
diabetes, life expectancy, treatment burden and vulnerability to
hypoglycaemia. However, none of the goals set for an older popula-
tion have been validated in dedicated clinical trials, let alone cardio-
vascular outcome clinical trials. The UK Prospective Diabetes
Study21,22 excluded patients at the age of ≥65 years and the subgroup
analysis of other trials (ACCORD, ADVANCE, VADT) evaluating
the role of glycaemic control in the prevention of cardiovascular
outcomes did not result in conclusive findings.23-27 This lack of stan-
dardized treatment goals poses a challenge for those who design clini-
cal trials. Investigators caring for older patients who have shorter life
expectancy, comorbidities, polypharmacy, increased risk of complica-
tions and of adverse events, as well as geriatric syndromes such as
memory impairment and frailty may be reluctant to follow stringent
glycaemic goals set in a study.
While long-term benefits of lowering blood glucose have not
been studied and hence are unproven in older adults, there is an
agreement that detrimental effects of hypoglycaemia in older individ-
uals are more pronounced and clinically relevant compared with those
in younger individuals. Older age is a well-recognized predisposing
factor for any type of hypoglycaemia in diabetes.28,29 The conse-
quences of hypoglycaemia in older patients may range from deterio-
rating quality of life, ambulatory difficulties, falls, fractures and
cognitive impairment to grave life-threatening episodes of seizure,
coma, cardiovascular events, arrhythmia and hospitalizations.30,31
Therefore, balancing the potential benefits of improved glycaemic
control and the risk of hypoglycaemia is an important goal of diabetes
treatment for older patients.
2.2 | Acceptability of newer treatment options in
older patients
Conventionally used glucose-lowering treatments such as insulins,
sulphonylureas and meglitinides increase the risk of hypoglycaemia,
which for decades has been considered a price to be paid for
improved glycaemic control. Recent oral and injectable therapies that
per se do not increase the risk of hypoglycaemia may be used as
stand-alone or combination treatment.
Over the last few years, studies for some of the hypoglycaemia-
neutral sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and
glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown an
additional benefit of lowering cardiovascular events in patients with
type 2 diabetes with cardiovascular disease32-37 or without.38 These tri-
als have involved a large proportion of older patients, yet overall study
populations were generally younger and may have had different charac-
teristics than typical older patients. Demonstrating consistency of find-
ings for the overall cardiovascular outcomes study population and older
participant subgroups may support extrapolation of results.38-40 How-
ever, despite evidence supporting use of newer hypoglycaemia-neutral
treatments, in real world clinical practice, older patients including those
at high risk of hypoglycaemia continue to use sulphonylureas and insu-
lin for a variety of reasons.20
Cardiovascular benefits may become apparent in a long-term per-
spective and, therefore, may be irrelevant in the case of patients with
limited life expectancy. On the other hand, rare adverse events of
therapies may be of greater concern in older patients. Examples
include volume depletion in older patients using SGLT-2is,41,42 nausea
and gastrointestinal adverse events with GLP-1 RAs,43 or increased
risk of fractures and heart failure with thiazolidinediones.44,45 Weight
loss, a benefit of SGLT-2i or GLP-1 RA therapy, may not be desirable
for many older patients who are already lean. Finally, the higher costs
of the novel diabetes treatments may prevent broader access to older
individuals.
Thus, shorter life expectancy, comorbidities, polypharmacy,
increased risk of complications and of adverse events, geriatric syn-
dromes such as memory impairment and frailty, and lastly economic
considerations make treatment goals and therapeutic choices in older
patients different from those accepted as standard for treatment in
younger patients.
2.3 | Issues with participation of older patients in
clinical trials
Many clinical trials enrol participants who are considerably younger
than a representative population of patients affected by the diseases
studied. This problem has been reported across different therapeutic
areas such as heart failure, hypertension, Alzheimer's disease, colorec-
tal cancer and depression, as well as diabetes.46,47 Older patients may
be excluded from participation because of explicitly set age limits or,
much more often, because inclusion and exclusion criteria indirectly
limit their participation based on comorbidities, polypharmacy, cogni-
tive impairment, short life expectancy and other factors.14,47 Even if
the enrolment and exclusion criteria allow participation of older peo-
ple in clinical trials, relatively few might get enrolled even if their
enrolment is desired. Barriers leading to their underrepresentation
may be related to concerns about greater drug toxicity, poor compli-
ance, mobility issues and reliance on assistance of caregivers. Even
if they are enrolled, older study participants may not represent the
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TABLE 2 Problems and issues in diabetes trials involving older patients
Problems and issues in diabetes
trials involving older patients
relevant to
Description Potential solutions
Investigators Lack of experience in assessment
and care of older patients.
Additional training offered to the site staff including information
about conducting trials with regards to communication,
sensory, mobility and cognitive problems in older people.46
Lack of suitable patients in typical
trial centres.
Involvement of different types of sites (geriatric clinics, primary
care, internal medicine, community-based clinics and services).
Lack of motivation to recruit older
patients if younger ones are
eligible.
Setting age-specific enrolment targets.46
Therapeutic inertia. • Involvement of investigators and patient advocates in
protocol development.
• Simplification of the protocol.
• Monitoring treatment decisions (e.g., in electronic database).
Study participants Lack of interest or inability to
participate in studies.
• Incentives for patients (e.g., reimbursement, meals,
education).
• Involving primary care practices rather than secondary.
• Social interactions, addressing altruism as a factor improving
participation.46
Lack of awareness of trial. Information, advertising through appropriate channels used by
the intended age group.
Concerns about safety of the study
treatment.
• Understandable study treatment information, simplification
of informed consent.
• Additional time offered to older patients.
Need assistance to get to the study
sites or follow the protocol.
• Provision of care for those the patients are responsible for.46
• Logistical support (transportation to the sites or study visits
at home/institution where patients stay).
• Home-based trials, visits, investigative procedures.46
• Simplification of protocols, flexible time for the study visits.
• Avoidance of additional visits, i.e., telephone visits, other
indirect contacts.
No functional characterization. Introduction of simple user-friendly tools to assess comorbidities
and functional status (frailty, cognitive function).
Discontinuations. Study sample size adjustments based on higher than expected
dropouts.
Caregivers Lack of motivation to ensure trial
participation.
• Incentives for caregivers to motivate compliance with the
protocol.
• Providing incentives for transportation, parking, etc.
• Providing caregiver with specific information and literature to
support their critical role.
• Collecting patient-reported outcomes from caregivers.
Facilities where patients stay Need for acceptance from the
institutions’ leadership and staff.
Informed consent from family,
caregivers and not from a patient.
Establishing good communication and relationship with facility
administration and staff including provision of study
information brochures, published research and face-to-face
communication.
Mistrust of clinical research. Building awareness and trust by explaining the need for clinical
studies.
Perception of additional workload
and cost.
• Reimbursement and recognition for the facility staff.
• Discussion of costs, informed consent, and other potential
issues early.
• Engaging facility management and staff at the time of
enrolment.
• Periodic follow-up meetings with the facility management
and staff.
(Continues)
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real-world geriatric population in terms of functional status and com-
orbidities as relatively fit individuals are more likely to participate in
clinical trials. Functional characterization of the older study partici-
pants and assessment of frailty remains exceptional rather than a rou-
tine procedure in diabetes clinical research.
Older patients with diabetes typically attend different types of
clinics than the typical diabetes and endocrine clinical research sites.
They may receive diabetes care from their primary care clinics, geria-
tricians, internal medicine clinics or institutional health care profes-
sionals (Table 2). Many receive their care through assisted living
services while in nursing homes or chronic care facilities. Older
patients commonly have multiple comorbidities and thus conflicting
priorities, and limited time and interest in participation. They may not
be able to reach the sites or require caregiver assistance to get to the
site for study visits. It is particularly difficult for protocols with multi-
ple and long study visits, e.g., in case of multiple tests or procedures
that require remaining at the investigative sites for hours. Telephone
discussions, which are common for protocols requiring frequent moni-
toring and treatment adjustments such as insulin titrations, may
address this problem to some extent. However, frequent calls con-
tinue to be a burden as common age-related sensory or memory
impairments can make telephone discussions difficult.
Investigators and site staff may lack expertise in managing
older patients and may be reluctant to pursue glycaemic targets
that may be perceived as ambitious and treatments that require
therapy adjustments. Thus, in trials requiring changes or intensifi-
cation of therapy such as insulin titration studies, we observe the
phenomenon of so-called “clinical inertia”, where the treatment
decisions are delayed, or the protocol guidance is not fully
followed. Inertia in clinical trials probably reflects conflict of the
protocol with the usual clinical practice to “start low and go slow”
in older participants. On the other hand, study participants them-
selves may be non-compliant with the protocol. Increasing age and
a variety of other factors may increase risk of non-adherence to
the clinical study protocols among older participants, and sponsors
might consider implementation of preventive measures to help
patients at risk to complete the trial successfully.48
Researchers should also consider strategies to prevent dropouts
or discontinuations,49 as the likelihood of discontinuation because of
adverse events might be higher among older patients. Demanding
protocols that are manageable in younger populations might turn out
to be too burdensome for older patients, particularly in longer stud-
ies.50 Sample size calculations should account for dropouts higher
than those observed in “typical” populations. It might be necessary to
offer incentives for both patients and their caregivers to ensure their
continued interest in study participation through increasing the
benefit-risk ratio for participating in the clinical trial.49
2.4 | Difficulties in proper characterization of
patients
Older patients are inherently heterogeneous and require characteriza-
tion depending on the underlying trial objectives.51 This characteriza-
tion should ensure that the enrolled patients resemble a real-world
population of patients. Two of the most important elements of char-
acterization are the functional status and comorbidities of the patient.
Frailty has a major impact on treatment decisions in the real world, yet
we are not aware of any study where this has been captured (except in
IMPERIUM, as will be discussed in Section 3). Comorbidities and frailty
should essentially be assessed at baseline to understand the character-
istics of the study participants. In many instances, functional
status should be evaluated throughout the trial to understand if the
study treatment might impact it. Significant changes in functional status
[measured by the Short Physical Performance Battery (SPPB)] in older
participants with diabetes are evident after 1 year of follow-up when
the intervention was resistance exercise, nutritional education, and
optimizing glycaemic and blood pressure control.52 However, a longer
period of trial duration may be required to see changes in functional
status if the intervention was solely linked to blood glucose regulation.
TABLE 2 (Continued)
Problems and issues in diabetes
trials involving older patients
relevant to
Description Potential solutions
Study design, goals and endpoints Lack of accepted standards of
treatment and treatment goals in
older patients.
Need for earlier involvement of stakeholders (clinicians, patients,
caregivers, and payers), at the stage of study design
development.
Need for individualization of therapy
goals (no “one size fits all”
endpoints).
Individualization of glycaemic targets.
Enrolled patients may not represent
real-life population.
Conducting clinical trials in primary care centres rather than in
specialty care.46
Study sponsors High costs and complexity of the
trials because of higher numbers
of patients, costs associated with
support for patients and
caregivers (e.g., transportation).
Setting evidence-based minimal requirements for participation
of older patients and specific subgroups by regulatory
agencies and ethical review boards; providing regulatory
incentives for successful inclusion of older patients.
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TABLE 3 Tools to assess frailty, functional status and comorbidities
Tool Information provided Clinical research and practice use
Functional status including frailty
Fried Score53 It is originally based on 5 components of physical
frailty (3 questions and 2 procedures). Questions
are based on weight loss, exhaustion and low
physical activity; and procedures measure gait
speed and hand grip strength. It is scored out of
5: 0 (robust/not frail); 1-2 (pre-frail), and 3-5
(frail).
It is less frequently used as it involves 2 practical
measures/procedures. It is also seen as a
physical frailty measure only.
CSHA Clinical Frailty Scale54 It categorizes frailty as: very fit, well, well with
treated comorbid disease, apparently vulnerable,
mildly frail, moderately frail or severely frail.
Visual representation and description in
7 categories; easy to apply; and good for
encouraging clinicians to think of frailty in
clinical settings.
CSHA frailty index54,55 Original model calculates relative frailty, fitness and
severity based on 70 deficits that include
presence and severity of current diseases, ability
in ADLs, and physical signs from clinical and
neurologic exams.
It is not practical to use in clinical setting unless it
is represented by the shorter electronic frailty
index, which can be captured on electronic
primary care databases in some countries using
routine clinical data.
FRAIL Scale56 It is based on 5 components: fatigue, resistance,
ambulation, illness and loss of weight. It is scored
from 0 to 5, with 3-5 termed as frail, 1-2 as pre-
frail, and 0 as robust. It has high predictive value
for future disability.
It does not require face-to-face consultation. It is
now becoming measure of choice in many
clinical settings and clinical trials. It is validated
in multiple populations.
Short Physical Performance Battery
(SPPB)57
It is an evaluation tool for lower limb function that
combines gait speed, chair stands and balance
tests. It has high predictive ability for mortality,
care home admission and future disability.
It requires little training. It is a quick assessment
that is becoming a standard objective measure
of functional change in clinical trials involving
older people.
Gait Speed58 It uses gait speed as a measure of functional
capacity and predictor of health outcomes. Low
gait speed can predict higher risk of
hospitalization and need for a caregiver.
This is one of the three domains of evaluation in
the SPPB. It is easy to measure and there are
population-based reference values available.
Electronic frailty index (eFI)59 It categorizes presence of frailty as mild, moderate
or severe based on existing electronic health
records in primary care in the UK without
additional assessments being required. It uses
36 deficits based on 2171 read codes.
It is not a diagnostic tool, but a risk stratification
tool. When the score is high (indicating
probable presence of frailty), direct clinical
evaluation is required for diagnosis.
CSHA functional scale It scores based on 12 ADLs as 0 (independent in
carrying the ADL), 1 (needs assistance), or
2 (incapable).
–
Comorbidity
Cumulative illness rating scale (CIRS)60 A measure of multimorbidity and particularly of the
burden of chronic medical illness. It has
14 individual system scores, giving a score of
0-56.
After previous training, the CIRS has good inter-
and intra-rater reliability. It can be used in
community/family practice.
Charlson comorbidity index (CCI) and its
adaptations (Deyo CCI, Romano CCI,
D’Hoore CCI, Ghali CCI, Quan CCI)61,62
It predicts the 1-year mortality for an individual
with a range of comorbidities.
It is a widely used and a recommended index
when outcome of interest is mortality.
Elixhauser comorbidity index (EI)63 It uses a comprehensive set of 30 comorbidities to
predict mortality. These are based on the
international classification of diseases (ICD).
It is used to predict in-hospital resource use
and/or mortality.
Index of coexisting disease (ICED)64 Each condition or limitation experienced by the
patient has a score based on its severity and
level of physical impairment.
It was initially shown as a strong predictor of
death in dialysis patients.
Chronic disease score (CDS)65 It uses medications to identify comorbidities. –
RxRisk and RxRisk-V66 It is an all-age risk assessment using outpatient
pharmacy database to identify chronic diseases
and predict future health care costs.
It is recommended when evaluating health care
utilization.
(Continues)
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There are no gold standard tools established to assess either functional
status or comorbidities that could be consistently used in clinical diabe-
tes trials but we do list some of the widely used tools (see Table 3).
Recently, EMA provided guidance on the characterization of older
patients in a reflection paper that recommends SPPB as the instrument
that best fulfils criteria for the prognostic value, validation status, feasi-
bility and ease-of-use, time needed, ease of investigator training and
cost.13,57 The geriatric assessment tool, Gait Speed, was recommended
as an alternative when SPPB use is not feasible in clinical trials.58
While not a standard procedure in diabetes clinical trials, assess-
ment of the metabolic phenotype might help to understand better the
probable disease progression, treatment modalities, intensity and
goals of therapy of study participants.57 A recent analysis identified
different subtypes of adult-onset diabetes based on the clustering of
clinical characteristics.57 One phenotype was found to be typical for
older people whose disease seems to have the mildest clinical
course.51 However, not all elements of phenotyping, which is based
on body mass index, age at onset of diabetes, homoeostasis model
assessment estimates of β-cell function (HOMA2-B) and insulin resis-
tance (HOMA2-IR) and glutamic acid decarboxylase antibodies, are
used routinely in diabetes trials or clinical practice.
2.5 | Choice of clinical trial endpoints
In addition to endpoints such as HbA1c change, proportions of
patients meeting HbA1c targets, weight change, change in fasting
plasma glucose, or adverse events, other clinical trial endpoints
reflecting changes relevant from patients’ and caregivers’ perspective
may be useful for diabetes trials involving older people. When
assessing efficacy of glucose-lowering therapy, clinical trial sponsors
should consider the need to individualize glycaemic goals and avoid
hypoglycaemia. Composite endpoints such as achievement of HbA1c
goal of ≤7.0% (≤53.0 mmol/mol) without hypoglycaemia have been
used in diabetes trials over the years.70,71 However, individualization
of therapy goals remains unaddressed. We are aware of one
dipeptidyl peptidase-4 inhibitor study that adopted individual
glycaemic targets for older patients,72 but no detailed information is
available about specific targets and the decision process in choosing
them for individual patients.
2.6 | Hypoglycaemia as a study endpoint
It is not clear which category of hypoglycaemia is most suitable as an
endpoint or for inclusion in the composite primary endpoint relevant
for older patients. A growing body of evidence supports the notion
that all episodes of hypoglycaemia with blood glucose levels
<3.0 mmol/L (54.0 mg/dL) are relevant.73 Apart from conferring risk
of morbidities, such episodes negatively affect quality of life, result in
reluctance to advance therapy and affect adherence to diabetes ther-
apies.74,75 The most complete understanding of hypoglycaemia risk
might come from continuous glucose monitoring studies that so far
have rarely been performed in older patients with type 2 diabetes
because of technical complexity and added burden of clinical trial pro-
cedures. Availability of novel continuous glucose monitoring systems
and flash glucose monitoring may broaden the opportunity for use in
older patients and detect otherwise overlooked episodes of
hypoglycaemia, e.g., nocturnal episodes and episodes that patients are
unaware of.76
However, considering only hypoglycaemia episodes (irrespective
of severity) does not reflect the impact hypoglycaemia has on patients
and caregivers. Assessment of discomfort and disruption created by
hypoglycaemia is of importance for older patients. Thus, further study
TABLE 3 (Continued)
Tool Information provided Clinical research and practice use
Cognitive function screening
Mini-Mental State Examination (MMSE)67 It is usually scored out of 30, with a score less than
24 indicative of “cognitive impairment”.
It is commonly used and highly validated in
different populations and languages. It can be
a disadvantage in poorly educated people or
those with poor vision. It is now copyrighted
and may require a fee to be paid for use.
Mini cog68 It consists of a 3-step test: Registration of 3 words,
a clock test and then the recall of the 3 words.
It takes 3 min to complete; has varied scoring
systems, but easy to employ with minimal
training; less affected by language or
education. It has been validated in patients
with diabetes in primary care.
Montreal cog (MoCA)69 This is a rapid screening instrument for mild
cognitive impairment. It scores out of 30 points
and assesses attention and concentration,
executive functions, memory, language, visuo-
constructional skills, conceptual thinking,
calculations and orientation. A score of 26 is
rated as normal.
Is available in more than 40 languages/dialects
but not all versions have been validated. Now
requires a fee to have researchers trained in its
use.
Abbreviations: ADL, activity of daily living; CSHA, Canadian Study of Health and Aging.
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is needed to investigate outcome measures best suited for older
patients, which would reflect the individual success of therapy and
burden of associated hypoglycaemia. Patient-reported outcomes,
measures of quality of life, costs of treatment and caregiver-reported
outcomes may help to understand the full impact of the disease and
treatment.
Because of limitations and problems encountered in randomized
clinical trials, other types of clinical research may be better suited to
evaluate certain aspects of glucose-lowering treatments among older
individuals. Real-world evidence (RWE) studies that collect evidence
in real clinical care, home or community settings may create the way
to involve study participants who otherwise are not enrolled in clinical
trials conducted at academic centres and research sites.77 In addition,
RWE research offers greater external validity in comparison with ran-
domized clinical trials as they involve patients with coexisting illnesses
and concomitant therapies.77 Drawbacks of RWE research include the
innate risk of study bias, inability to control variability, and limited
ways to assure completeness and quality of data collected. These
problems may be addressed to some extent through pragmatic studies
that aim at preserving a real-world practice setting by minimizing
inclusion and exclusion criteria and reducing the burden on partici-
pants by limiting the number and complexity of study visits and proce-
dures.78 However, pragmatic studies typically assess interventions
delivered to randomized populations in an unblinded fashion. The
unobtrusive collection of data makes pragmatic trials suitable for the
collection of adverse events that are important for patients, such as
cardiovascular events, death, disability or hospitalizations, but may
limit possibilities of assessment of minor adverse events, signs, symp-
toms and quality of life. Importantly, RWE and pragmatic studies pro-
vide limited opportunities for functional characterization of study
participants. Another important limitation of these studies is low sen-
sitivity to detect hypoglycaemia. Studies based on retrospective
collection of hypoglycaemia events using medical records or question-
naires may miss many hypoglycaemic episodes, leading to the under-
estimation of hypoglycaemia risk.79 Reports of hypoglycaemic
episodes that require hospital admission or emergency room visit may
be considered reliable, as they are recorded and create a memorable
and reportable experience.80 However, these episodes account for
only a minority of overall episodes.
3 | LEARNINGS FROM THE IMPERIUM
TRIAL
3.1 | The IMPERIUM trial
We conducted the IMPERIUM randomized controlled trial16 to
address the knowledge gap related to the use of novel glucose-
lowering therapies that per se do not increase risk of hypoglycaemia
(“glucose-dependent mode of action”) in older patients with type 2 dia-
betes. We enrolled vulnerable (moderately ill and/or frail) patients
aged ≥65 years. While use of agents such as dipeptidyl peptidase-4
inhibitors and GLP-1 RAs seems to be justified in older patients who
are more vulnerable to hypoglycaemia, these patients are frequently
treated with agents that are “non-glucose dependent” in their blood
glucose lowering action such as sulphonylureas and insulin. We com-
pared two treatment strategies using several marketed oral antihyper-
glycaemic medications (OAMs) and injectable treatments (either GLP-
1RA or insulin glargine). Strategy A adopted “glucose-dependent”
therapies with non-sulphonylurea OAMs and GLP-1RAs if injectable
therapy was needed. Strategy B reflected a more traditional treatment
approach with sulphonylureas as a preferred OAM used either in
monotherapy or in combination, and insulin glargine (100 units/mL) as
a first-line injectable treatment, if needed. The trial assessed the rela-
tive success of Strategy A as compared with Strategy B in achieving
and sustaining glycaemic control in the absence of episodes of clini-
cally significant hypoglycaemia.
Many aspects of the design and study conduct were novel; there-
fore, we decided to begin the trial planned to last 72 weeks with an
internal pilot phase involving approximately 20% of the full study pop-
ulation treated for at least 24 weeks. The results of this pilot study
did not show a significant difference between the two treatment
strategies (P = 0.67). The conditional power for statistical significance
of the primary outcome indicated low probability of the study success
(conditional power = 0.05), and hence the study was terminated after
the interim analysis. While the study is considered as “failed”, the
learnings from it might inform future research of this kind and are
worthy of reporting to the clinical research community.
3.2 | Enrolling patients and characterizing study
participants
Enrolment of patients at typical diabetes trial sites represented signifi-
cant challenges, leading to extension of the enrolment period and
searching for suitable patients at other endocrine/diabetes and pri-
mary care sites. One of the unique features of the trial was the
attempt to characterize health and functional status of the enrolled
patients to ensure that study participants not only met age criteria,
but also were representative of the older population, i.e., they had
comorbidities and/or were frail. We adopted the Total Illness Burden
Index (TIBI) to assess comorbidities and Clinical Frailty Scale (CFS)
Index to confirm eligibility criteria. While use of CFS is easier and intu-
itive, adoption of TIBI required more effort. In the IMPERIUM trial,
TIBI was calculated by a clinician based on the patients’ responses to
15 questions. Scores calculated during the study were sent to the
coordinating centre for validation. These tools helped to identify vul-
nerable patients, but we found that mean TIBI and CFS scores were
relatively low; mean ± SD of TIBI = 3.8 ± 2.4 and CFS = 4.1 ± 0.6,
with only one-third of the study subjects at least moderately ill and
frail. Thus, we had enrolled patients who were healthier and function-
ing better than we expected. Interestingly, we did not note differ-
ences between patients with high and low TIBI and CFS scores in
terms of likelihood of reaching treatment target, developing
hypoglycaemia or decreasing HbA1c. We noted that investigators
tended to assign a higher HbA1c target (7.5%-7.9%, 59-63 mmol/mol)
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to patients with a higher CFS at baseline (≥5). Based on this experi-
ence, we recommend that future trials should seek sites that are able
to enrol more study participants who are ill and frail. Researchers
should seek study sites other than diabetes and endocrine clinics.
Primary care practices, geriatric clinics, community-based clinics and
services, and long-care facilities might offer greater access to potential
study participants. Identifying such centres and establishing collabora-
tion poses additional challenges. Table 2 provides suggestions to help
establish such new research sites. We strongly recommend functional
characterization of study participants either with CSF or another sim-
ple tool. We also suggest setting stringent eligibility criteria related to
the health and functional status, otherwise healthier and fitter study
participants are likely to be enrolled.
3.3 | Choosing individualized treatment goals
Investigators in our study had a choice of allocating three different
target HbA1c values to patients: 7.5%-7.9% (59-63 mmol/mol);
7.0%-7.4% (53-57 mmol/mol); and <7.0% (<53 mmol/mol). Treat-
ment was to be adjusted, either uptitrated or intensified if actual
HbA1c was higher than the target value. Investigators could choose
a specific target based on their best clinical judgement; however,
some guidance was provided in the protocol. Assessment criteria
included patients’ dependence on others, cognitive and functional
status, risk of hypoglycaemia, duration of diabetes, presence of
complications and comorbidities, and life expectancy. Overall, the
most stringent goal of HbA1c <7.0% (<53 mmol/mol) was chosen in
approximately 50% of trial participants, while the highest HbA1c
goal was chosen for approximately 12%; consistent with the overall
better than expected health of enrolled patients. We tried to evalu-
ate the impact of patient characteristics on the selection of individu-
alized treatment targets.
Of several determinants, high baseline HbA1c (≥8.5% or
≥69 mmol/mol) and CFS score of ≥5 positively correlated with the
choice of the highest target HbA1c values. There was no correlation
between the target HbA1c chosen and gender, body mass index
<35 kg/m2, previous sulphonylurea use, TIBI score or presence of
renal disease. This might reflect lack of understanding among investi-
gators on how frailty or comorbidities should impact treatment choice.
3.4 | Treatment strategies versus specific
treatments
The IMPERIUM study evaluated treatment strategies rather than spe-
cific treatments. We believe that such studies are needed, taking into
consideration the growing variety of therapeutics available to patients
and clinicians. While clinical trials sponsored by pharmaceutical com-
panies typically investigate specific drugs, studies evaluating more
real-life scenarios are presumably clinically more relevant. Another
advantage was that the investigators had freedom to use multiple
drugs from the same therapeutic class at variable doses. This was
possible as study participants were provided prescription cards rather
than dispensing drugs. However, it also turned out to be difficult for
the clinical study staff, who are more accustomed to simple and
straightforward treatment requirements.
3.5 | Clinical inertia
Despite the familiarity with OAMs and injectable treatments used in
the trial, and that all treatments were to be used in accordance with
the product labels, we noted the problem of clinical inertia within the
trial. The trial investigators tended to delay the decision to uptitrate
and/or intensify the treatment despite the patient not reaching the
individual HbA1c target at consecutive visits. As pursuing glycaemic
goals was pivotal for the success of the study that meant to provide a
conclusive answer to the main hypothesis tested, we had to imple-
ment additional monitoring of the trial decisions. Investigators were
contacted and reminded about the action needed (dose adjustment of
existing treatment or prescribing next line therapy) if no change of
treatment was recorded at two consecutive visits at which HbA1c
remained above the individualized target value. Overall, approximately
60% of patients achieved their HbA1c target value at the last study
visit (65.3% with Strategy A and 59.1% with Strategy B). Within each
treatment group, patients with HbA1c ≥8.5% (≥69 mmol/mol) at base-
line probably experience more clinical inertia than those who had
lower HbA1c (Strategy A: P = 0.049; Strategy B: P = 0.048).
3.6 | Defining hypoglycaemia, the right way
The primary endpoint of the trial was a composite outcome of achiev-
ing and maintaining target HbA1c while avoiding clinically relevant
hypoglycaemia. We defined clinically relevant hypoglycaemia as epi-
sodes of severe hypoglycaemia; repeated episodes of hypoglycaemia
as confirmed by blood glucose level of ≤70 mg/dL (≤3.9 mmol/L)
causing significant disruption of the patient's activity; or repeated epi-
sodes of hypoglycaemia with blood glucose level of <54 mg/dL
(<3.0 mmol/L). While the composite endpoint aimed to reflect clini-
cally meaningful problems of treatment risk-benefit balance, this defi-
nition of clinically relevant hypoglycaemia was found to be too
stringent. It disregarded a clear majority of hypoglycaemia episodes as
“not relevant”, leading to the conclusion that both treatment strate-
gies were similar in terms of clinical outcomes. The lower risk of total,
documented symptomatic and asymptomatic hypoglycaemia with
Strategy A was not considered during the decision to terminate the
trial even though these findings are highly relevant for clinical prac-
tice. Very few “clinically relevant hypoglycaemia” episodes were
reported in our trial despite the significant improvement in mean
HbA1c. Adoption of less stringent definitions in future research might
help in capturing all clinically relevant episodes. The recent position
statement, proposed by the International Hypoglycaemia Study Group
and adopted by the ADA, EASD and EMA among others, offers a
more useful endpoint for future trials.73
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4 | CONCLUSIONS AND FUTURE
PERSPECTIVES
In conclusion, we believe that assessment of efficacy and safety of
glucose-lowering treatments among older patients with diabetes remains
suboptimal. With the growing population of older people with diabetes,
it becomes an urgent and relevant challenge that needs to be addressed
in future clinical research. To identify appropriate glucose-lowering treat-
ments or treatment regimens, a paradigm shift is warranted in conducting
clinical trials in older adults. Studies that are more thorough, conducted
in patients with comorbidities and impaired functional status, and with
various degrees of frailty are necessary to understand fully the risk-
benefit ratio of therapies used in older individuals. While conducting dia-
betes clinical trials in older people poses significant operational chal-
lenges, including the need to reach atypical research sites, it is
nevertheless a broad societal responsibility to ensure that such trials take
place. Successful completion of trials requires new strategies to improve
enrolment, study design and adoption of study endpoints to ensure
retention of patients in the trials and compliance with the protocol. More
research is needed for informed therapy goal-setting, to allow individuali-
zation of treatment targets and to adopt clinical trial endpoints rep-
resenting benefits and risks that are most relevant from the perspective
of older patients and their caregivers.
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